OPEN UP TO A WHOLE NEW APPROACH TO BPH
The UroLift® System Treatment

A minimally invasive approach to treating BPH that lifts or holds the enlarged prostate tissue out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.

- Immediate, visible result
- Rapid symptom relief
- No tissue removal or ablation
- Minimal downtime
- Preservation of sexual function

Roehrborn, J Urology 2013 LIFT Study
Redefining BPH Treatment

11.9 Million Men in the U.S. are Treated for BPH/LUTS

Watchful Waiting

48%

5.7 Million Patients

Drugs

51%

6.1 Million Patients

Surgery/Procedure

Yet Only 1%

Elect Surgery

142,000 Patients

NeoTract US Market Model estimates for 2013 based on IMS Health Drug and Procedure data
The UroLift® Delivery Device is inserted transurethrally through a rigid sheath under cystoscopic visualization in order to reach the targeted area of obstruction.

The obstructing prostatic lobes are retracted by small permanent UroLift Implants which are deployed via a needle that comes out of the delivery device.

Each UroLift Delivery Device contains one UroLift Implant. Typically, 4-5 UroLift Implants are placed into the prostate.
UROLIFT®

Significant Improvement Without Significant Downsides

0% Ejaculatory Dysfunction
0% Erectile Dysfunction

No instances of de novo, sustained erectile or ejaculatory dysfunction.


1. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

*ED – Erectile Dysfunction   **EjD – Ejaculatory Dysfunction
Strong Clinical Results

- Endoscopic results can be immediately confirmed post-procedure.
- Patients may experience symptom relief as early as 2 weeks post-procedure.
- UroLift® System treatment does not preclude future UroLift, TURP or laser procedures.

Canadian J. of Urology, Multi-Center Study (n=51) 2014
British J. Urology, Crossover Study (n=53) 2013
J. of Urology, L.I.F.T. Study (n=206, 1 yr) 2013
J. of Sexual Medicine, USA Sexual Function (n=140, 1 yr) 2013
EU J. of Urology, EU Registration (n=102, 1 yr) 2013
Archivos Españoles Urología, Spanish Study (n=20) 2013
Urology, 2 Year Multi-Center Study (n=64, 2 yr) 2012
J. Sexual Medicine, Preserves Sexual Function (n=64, 1 yr) 2012
Progrès en Urologie, Single Center French Study (n=4) 2012
Canadian J. of Urology, Technique (n=50) 2012
British J. Urology, First in Man (n=19, 1 yr) 2011
L.I.F.T. Study Results Corroborate Prior Studies

206-patient L.I.F.T. IDE Study, a multi-center, randomized, blinded study. All primary and secondary endpoints were met. Patients experienced rapid symptomatic improvement, increased urinary flow rates, preserved sexual function and a significant improvement in Quality of Life.


<table>
<thead>
<tr>
<th>Measure</th>
<th>UroLift</th>
<th>Control</th>
<th>Difference</th>
<th>12 Month UroLift</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUASI</td>
<td>11.1</td>
<td>5.9</td>
<td>0.003</td>
<td>10.8</td>
</tr>
<tr>
<td>Qmax (ml/s)</td>
<td>4.28</td>
<td>1.98</td>
<td>p =0.005</td>
<td>4.02</td>
</tr>
<tr>
<td>QOL</td>
<td>2.2</td>
<td>1.0</td>
<td>p &lt;0.001</td>
<td>2.4</td>
</tr>
<tr>
<td>BPHII</td>
<td>3.9</td>
<td>2.1</td>
<td>p &lt;0.001</td>
<td>4.0</td>
</tr>
</tbody>
</table>

No instances of de novo, sustained erectile or ejaculatory dysfunction
For additional information and surgical videos visit UroLift.com

Customer Service • 877.408.9628
Reimbursement Resource Center • 800.651.8247

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is to improve the standard of care for patients with Benign Prostatic Hyperplasia (BPH), a broadly underserved market. Our first product is the UroLift® System, a minimally invasive device designed to treat lower urinary tract symptoms (LUTS) due to BPH.